Summary (tl;dr)

The Drug Enforcement Administration (DEA) has extended critical telemedicine flexibilities for prescribing controlled substances through the end of 2026, preventing a potential "telemedicine cliff" that would have impacted patient access to care, while simultaneously being directed to expedite the reclassification of cannabis.

Essential Background

During the COVID-19 public health emergency, the DEA temporarily relaxed requirements of the Ryan Haight Online Pharmacy Consumer Protection Act, allowing healthcare providers to prescribe controlled medications via telemedicine without a prior in-person medical evaluation. These emergency flexibilities were initially set to expire at the end of 2025. Separately, cannabis has been classified as a Schedule I substance under the federal Controlled Substances Act for over 50 years, categorizing it as having no accepted medical use and a high potential for abuse.

The Full Story

Effective January 1, 2026, the Drug Enforcement Administration (DEA), in partnership with the Department of Health and Human Services (HHS), announced a fourth temporary extension of telemedicine flexibilities for prescribing Schedule II-V controlled substances, including buprenorphine for opioid use disorder, through December 31, 2026. This crucial action aims to prevent a "telemedicine cliff," which would have abruptly limited patients' access to care by reinstating pre-pandemic in-person visit requirements. The extension provides the DEA additional time to develop and finalize permanent regulations governing the remote prescribing of controlled substances.

Concurrently, in December 2025, President Trump issued an executive order directing federal agencies, including the DEA, to expedite the process of rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). This proposed reclassification would acknowledge cannabis's accepted medical value and lower potential for abuse, building on scientific findings from the Department of Health and Human Services and the Food and Drug Administration.

Why It Matters

The extension of telemedicine flexibilities is critical for maintaining continuity of care for millions of patients who rely on remote access to essential medications. This is particularly vital for individuals in rural or underserved areas, the elderly, and those with mobility limitations, as well as for patients receiving treatment for opioid use disorder. Without this extension, an abrupt disruption in care and a significant backlog of in-person appointments were anticipated.

The potential rescheduling of cannabis represents a monumental shift in federal drug policy, as it would be the first time in nearly a century that federal law would acknowledge cannabis's medical value. This change could significantly ease the passage of medical cannabis laws in states without them, reduce the stigma faced by medical cannabis patients, facilitate easier research into its therapeutic benefits, and improve access for patients nationwide. It also has substantial implications for the pharmaceutical industry and state-legal cannabis businesses by removing certain tax burdens. Separately, the DEA's repeated delays in setting annual opioid production quotas have raised concerns, with critics warning that these delays could lead to drug shortages and impact patients requiring these medications for conditions like chronic pain.

Geographic Location

• Washington, D.C., District of Columbia, United States (Drug Enforcement Administration (DEA) and Department of Health and Human Services (HHS) issued a temporary rule extending telemedicine flexibilities, and President Trump issued an executive order directing cannabis rescheduling)